The medical recommendations for adult LCH have been published in Orphanet Journal of Rare Diseases.

More ...
An­nu­al in­ter­na­tio­nal con­fe­rence of sci­en­tists, pa­tho­lo­gists and cli­ni­ci­ans discussing histiocytoses and their backgrounds. More ...
An International Community of Professionals Dedicated to Research and Treatment More ...
PubMed comprises more than 20 million citations for biomedical literature from MEDLINE, life science journals, and online books. More ...

European Union Clinical Trials Register of the European Medicines Agency

More ...

European Clinical Trials Database of the European Medicines Agency

More ...
Rare diseases in EU
Why do rare diseases need specific EU support? More ...
Euro Histio Net has received funding from the European Union, in the framework of the Public Health Programme. More ...
 
» Expert Histio Net » For Professionals » Guidelines » LCH adult » General Consideration  · 

General consideration

Author(s): Euro Histio Net Work Group for LCH Guidelines for adults (see introduction page), Created: 2012/07/26, last update: 2013/08/18

The etiology of LCH is unknown. LCH cells are clonal (except primary pulmonary LCH) [Willman et al 1994; Yousem et al 2001] and a cancer-associated mutation (BRAFV600E) was found in more than half of investigated specimens, indicating that LCH may be more a neoplastic (not a malignant!) disease than a reactive disorder, but the pathogenesis is still unclear [Badalian-Very et al 2010; Badalian-Very et al 2013]. Although apparent associations between LCH and malignant tumors have been recognized, these cases represent a minority of all LCH patients and the pathophysiologic relationship remains undefined [Egeler et al 1993].

The disease may affect any organ or system, more frequently bones, skin, and pituitary gland. Lymph nodes, liver, spleen, gut, the central nervous system, pituitary, and the hematopoietic system are less frequently affected. Lungs may be affected simultaneously or consecutively with other organs, but isolated pulmonary LCH (PLCH) occurs frequently in adults and may proceed to multisystem involvement. PLCH requires a different management in contrast to multi-organ involvement and is therefore discussed in a separate section.

Clinical manifestations of LCH vary depending on the organ or system affected, from self-healing disease to chronic recurrences. A rapid progressive form, seen in children, is usually not observed in adults. Langerhans cell sarcoma (malignant histiocytosis) can occur de novo or from an antecedent LCH [Lee et al 2006]. This paper will not cover other histiocytic disorders such as Erdheim-Chester disease (ECD), Rosai-Dorfman disease (RDD) or malignant histiocytosis. In cases of occurrence of LCH and ECD or RDD in the same patient, the management is based on the predominant disease.

Treatment options vary depending on disease extent and severity at onset. A uniform diagnostic work-up is necessary. One of the main problems of LCH in adults is the variety of potentially involved organs resulting in several physicians being consulted. Frequently only the most obviously affected site is considered and a complete examination is not done thus missing other sites of disease.

References

[Willman et al 1994] Willman CL, Busque L, Griffith BB, Favara BE, McClain KL, Duncan MH, Gilliland DG: Langerhans'-cell histiocytosis (histiocytosis X)--a clonal proliferative disease. The New England journal of medicine 1994 Jul 21; 331: 154 [PMID: 8008029]

[Yousem et al 2001] Yousem SA, Colby TV, Chen YY, Chen WG, Weiss LM: Pulmonary Langerhans' cell histiocytosis: molecular analysis of clonality. The American journal of surgical pathology 2001, 25: 630 [PMID: 11342775]

[Badalian-Very et al 2010] Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, Kuo FC, Ligon AH, Stevenson KE, Kehoe SM, Garraway LA, Hahn WC, Meyerson M, Fleming MD, Rollins BJ: Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010 Sep 16; 116: 1919 [PMID: 20519626]

[Badalian-Very et al 2013] Badalian-Very G, Vergilio JA, Fleming M, Rollins BJ: Pathogenesis of Langerhans cell histiocytosis. Annual review of pathology 2013 Jan 24; 8: 1 [PMID: 22906202]

[Egeler et al 1993] Egeler RM, Neglia JP, Puccetti DM, Brennan CA, Nesbit ME: Association of Langerhans cell histiocytosis with malignant neoplasms. Cancer 1993 Feb 1; 71: 865 [PMID: 8431870]

[Lee et al 2006] Lee JS, Ko GH, Kim HC, Jang IS, Jeon KN, Lee JH: Langerhans cell sarcoma arising from Langerhans cell histiocytosis: a case report. Journal of Korean medical science 2006, 21: 577 [PMID: 16778410]